Berenberg Bank reaffirmed their buy rating on shares of Genus (LON:GNS – Free Report) in a research report report published on Wednesday morning,London Stock Exchange reports. They currently have a GBX 3,350 target price on the stock.
Several other brokerages also recently commented on GNS. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Genus from GBX 3,100 to GBX 3,300 and gave the stock a “buy” rating in a report on Friday, January 16th. Shore Capital Group restated a “buy” rating and set a GBX 3,000 price target on shares of Genus in a report on Friday, January 16th. Three investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of GBX 3,216.67.
Read Our Latest Stock Report on GNS
Genus Stock Down 0.2%
Genus (LON:GNS – Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The company reported GBX 60.80 EPS for the quarter. Genus had a net margin of 7.07% and a return on equity of 9.70%. Equities analysts expect that Genus will post 70.9644323 earnings per share for the current year.
Insider Activity at Genus
In other news, insider Celia Baxter bought 1,728 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The stock was acquired at an average cost of GBX 2,893 per share, for a total transaction of £49,991.04. Insiders own 0.70% of the company’s stock.
About Genus
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands.
See Also
Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.
